Open Innovation Partnerships Daiichi Sankyo is actively pursuing external collaborations with biotech startups to explore new modalities and delivery platforms, including MNM delivery (Interna), predictive biomarkers (4D Path), and DNA origami nanoparticles (DoriNano). This signals a strong appetite for co-development, licensing, or research partnerships. Sales angle: position as a deal-sourcing partner, provide due diligence, or propose collaboration models (co-development, milestone-based payments).

ADC Leader Biomarkers The company's DXd ADC portfolio and emphasis on predictive biomarkers for ADC programs create opportunities to offer companion diagnostics development, biomarker assays, patient stratification analytics, and translational data services. Potential to engage for CRO/CMO services or collaborative assay development, accelerating ADC clinical programs.

Digital Health Advantage With Looker, AWS, BrightInsight and other cloud/analysis tools, Daiichi Sankyo maintains a data-rich, regulated digital health / cloud footprint. This openness to digital ecosystems suggests opportunities for advanced analytics, data governance, platform modernization, or regulated digital health product development partnerships. Propose services around data integration, analytics, and compliant digital health solutions.

Procurement & Ops Coupa usage indicates mature procurement processes and a focus on supplier management. This creates sales opportunities for procurement optimization services, supplier risk analytics, spend analytics, and software-enabled supply chain improvements that reduce cycle times and costs.

US Expansion & Partnerships Headquartered in New Jersey with an active Boston R&D presence and multiple announced collaborations in 2025-2026, the company is expanding its US ecosystem and external partnerships. BD play: identify US-based biotech and CRO partners, assist in co-development or licensing deals, and support market access planning for new modalities and ADC programs.